Literature DB >> 11917947

Busulfan-induced loss of Ph chromosome in chronic myeloid leukemia.

M Radojkovic1, S Ristic, M Colovic, B Todoric, K Krtolica.   

Abstract

We report a 44-yr-old female with Philadelphia chromosome positive chronic myeloid leukemia who was initially treated with busulfan, and clinical remission has been achieved. After 4 yr, low-dose busulfan therapy was started again and induced bone marrow aplasia. The patient spontaneously has recovered from aplasia, and complete cytogenetic remission with loss of Ph+ chromosome in bone marrow has been achieved. However, reverse-transcription-polymerase chain reaction analysis showed presence of the bcr-abl transcript in bone marrow.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11917947     DOI： 10.1385/MO:18:3:227

Source DB:  PubMed          Journal:  Med Oncol        ISSN： 1357-0560            Impact factor:   3.064


  10 in total

1.  Chronic myelogenous leukemia in chronic phase for 16 years: ongoing hematological remission and late minor cytogenetic response under minimal interferon maintenance therapy.

Authors:  M Fiegl; G Mitterbauer; A Weltermann; H Pirc-Danoewinata; U Jäger
Journal:  Leuk Lymphoma       Date:  1999-10

2.  Implications of prominent cytologic dysplasia persisting in the marrow of a patient with CML even after the spontaneous disappearance of the Philadelphia chromosome.

Authors:  G M Janković; A D Bogdanović; M D Colović; A V Novak; M Andolina; A Anagnostopoulos
Journal:  Am J Hematol       Date:  1996-07       Impact factor: 10.047

3.  Persistence of BCR-ABL genomic rearrangement in chronic myeloid leukemia patients in complete and sustained cytogenetic remission after interferon-alpha therapy or allogeneic bone marrow transplantation.

Authors:  J C Chomel; F Brizard; A Veinstein; J Rivet; A Sadoun; A Kitzis; F Guilhot; A Brizard
Journal:  Blood       Date:  2000-01-15       Impact factor: 22.113

4.  Spontaneous remission in a patient with chronic myeloid leukaemia.

Authors:  C Fegan; G Morgan; J A Whittaker
Journal:  Br J Haematol       Date:  1989-08       Impact factor: 6.998

5.  Spontaneous regression of cytogenetic and haematologic anomalies in Ph1-positive chronic myelogenous leukaemia.

Authors:  N Smadja; M Krulik; A A Audebert; A de Gramont; J Debray
Journal:  Br J Haematol       Date:  1986-06       Impact factor: 6.998

6.  Twenty-five year survival of chronic granulocytic leukaemia with spontaneous karyotype conversion.

Authors:  C R Singer; G A McDonald; A S Douglas
Journal:  Br J Haematol       Date:  1984-06       Impact factor: 6.998

7.  Molecular diagnosis of Philadelphia negative CML using the polymerase chain reaction and DNA analysis: clinical features and course of M-bcr negative and M-bcr positive CML.

Authors:  A Dobrovic; A A Morley; R Seshadri; E H Januszewicz
Journal:  Leukemia       Date:  1991-03       Impact factor: 11.528

8.  Hematological and cytogenetic response of interferon alpha 2b alone and combined interferon alpha plus cytarabine as a first-line treatment in chronic myeloid leukemia.

Authors:  E Tóthová; M Fricová; A Kafková; N Stecová; T Guman; S Raffac; M Hlebasková
Journal:  Neoplasma       Date:  2000       Impact factor: 2.575

9.  Molecular heterogeneity in complete cytogenetic responders after interferon-alpha therapy for chronic myelogenous leukemia: low levels of minimal residual disease are associated with continuing remission. German CML Study Group and the UK MRC CML Study Group.

Authors:  A Hochhaus; A Reiter; S Saussele; A Reichert; M Emig; J Kaeda; B Schultheis; U Berger; P C Shepherd; N C Allan; R Hehlmann; J M Goldman; N C Cross
Journal:  Blood       Date:  2000-01-01       Impact factor: 22.113

10.  Long-term follow-Up of the italian trial of interferon-alpha versus conventional chemotherapy in chronic myeloid leukemia. The Italian Cooperative Study Group on Chronic Myeloid Leukemia.

Authors: 
Journal:  Blood       Date:  1998-09-01       Impact factor: 22.113
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.